Read + Share
Seguin CL, Eckel A, Howard DH, Peters MLB, et al. Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent,
platinum-sensitive ovarian cancer in the United States. Gynecol Oncol 2026;211:178-184.
PMID: 42447659
|
 |
|
Seguin CL, Eckel A, Howard DH, Peters MLB, et al. Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent,
platinum-sensitive ovarian cancer in the United States. Gynecol Oncol 2026;211:178-184.
PMID: 42447659
|
|
|
|